Evolus (EOLS) PT Raised To $29 After Securing Financing - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Evolus (EOLS) Reports Publication of U.S. Phase III Pivotal Trial Results
March 21, 2019 8:02 AM EDTEvolus, Inc. (NASDAQ: EOLS) today announced the publication of the U.S. Phase III pivotal trial results for Jeuveau in Dermatologic Surgery. The article titled, Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results from 2 Identical Phase III Studies, is now available on the Journals Website and will be printed in the March 2019 issue.
The publication of the U.S. Phase III pivotal studies for Jeuveau, in a peer-reviewed journal with the prestige of Dermatologic Surgery, validates the... More
